The Role of PPM1D in Myeloproliferative Neoplasms

PPM1D 在骨髓增生性肿瘤中的作用

基本信息

项目摘要

Myeloproliferative Neoplasms (MPNs) are chronic hematologic disorders that are associated with significant morbidity and mortality and have the potential to progress to myelofibrosis and a blast phase. These diseases are characterized by a series of driver mutations that originate at the hematopoietic stem cell (HSC) level, however, the mechanisms driving disease progression are currently unclear. Current therapeutics for MPNs largely do not alter the disease course and it is therefore imperative to decipher the mechanisms underlying progression in order to identify new, more effective therapeutic agents. This proposal focuses on elucidating the role of Phosphatase Mg2+/Mn2+ Dependent 1D (PPM1D) in MPNs and evaluating it as a potential target to prevent MPN disease progression. PPM1D is involved in the maintenance and differentiation of HSCs and has recently been found to be mutated and/or overexpressed in a subset of MPN patients. Preliminary data shows that PPM1D mutation/overexpression leads to increased fitness of the JAK2 mutated MPN clone and that PPM1D inhibition depletes MPN HSCs. To further discern the consequences of dysregulated PPM1D in MPNs we will complete the following aims utilizing a multipronged approach involving primary MPN samples, human induced pluripotent stem cell (iPSC) lines and murine models: (1) Delineate the effects of PPM1D dysregulation on molecular signaling in JAK2V617F+ human hematopoietic cells, (2) Assess the in vivo consequences of PPM1D overexpression on MPN disease phenotype, (3) Identify therapeutic vulnerabilities of MPN cells with dysregulated PPM1D function. Experiments will employ a variety of techniques including biochemical assays, murine transplant models, primary hematopoietic cell colony assays, RNA sequencing and genotyping of transcriptomes. This proposal will also evaluate a novel strategy to target PPM1D in MPNs. Dr. Bridget Marcellino, an assistant professor at the Icahn School of Medicine at Mount Sinai, will be completing these studies under the mentorship of Dr. Ronald Hoffman, a scientific leader in the field of MPNs. She will have 75% of protected research time and will be provided the necessary resources to complete these studies. As an institution Mount Sinai is ideal for fostering the development of physician-scientists with academic seminars and state of the art facilities and resources. Bridget will also have an advisory committee consisting of Dr. Eirini Papapetrou at Mount Sinai, Dr. Ross Levine at Memorial Sloan Kettering Cancer Center, Dr. Dan Avi Landau at Weill Cornell Medical College and biostatisticians, Dr. Amylou Dueck and Heidi Kosiorek at Mayo Clinic. The career development plan outlined here will allow Dr. Marcellino to gain scientific expertise as well as increase her skills in manuscript and grant preparation. This proposal will facilitate Dr. Marcellino to achieve both her short term goal of publishing her findings and her long term goals of developing as a physician-scientist and establishing an independent research program focused on identifying novel therapeutic targets in MPNs.
骨髓增生性肿瘤(MPN)是慢性血液学疾病,其与显著的骨髓增生异常相关。 发病率和死亡率,并有可能进展到骨髓纤维化和急变期。这些疾病 特征在于起源于造血干细胞(HSC)水平的一系列驱动突变, 然而,驱动疾病进展的机制目前尚不清楚。MPN的当前治疗方法 在很大程度上不会改变疾病的进程,因此,必须破译其背后的机制, 研究进展,以确定新的,更有效的治疗药物。该提案的重点是阐明 磷酸酶Mg 2 +/Mn 2+依赖性1D(PPM 1D)在MPN中的作用,并评估其作为潜在靶点, 预防MPN疾病进展。PPM 1D参与HSC的维持和分化, 最近发现在MPN患者的亚组中突变和/或过表达。初步数据显示 PPM 1D突变/过表达导致JAK 2突变MPN克隆的适应性增加,并且 PPM 1D抑制耗尽MPN HSC。进一步辨别MPN中PPM 1D失调的后果 我们将利用多管齐下的方法完成以下目标,包括初级MPN样本、人类 诱导多能干细胞(iPSC)系和小鼠模型:(1)描述PPM 1D的作用 (2)评估JAK 2 V617 F+人造血细胞中分子信号传导的体内调节异常, PPM 1D过表达对MPN疾病表型的影响,(3)确定 PPM 1D功能失调的MPN细胞。实验将采用各种技术,包括 生物化学测定、鼠移植模型、原代造血细胞集落测定、RNA测序 和转录组的基因分型。该提案还将评估针对MPN中PPM 1D的新策略。 博士西奈山伊坎医学院助理教授布里奇特·马塞利诺将在 在MPN领域的科学领导者罗纳德霍夫曼博士的指导下完成这些研究。 她将有75%的受保护的研究时间,并将提供必要的资源来完成这些研究。 问题研究作为一个机构,西奈山是促进医生科学家发展的理想场所, 学术研讨会和最先进的设施和资源。布丽奇特还会有一个顾问委员会 包括西奈山的Eirini Papapetrou博士,纪念斯隆凯特琳癌症中心的Ross Levine博士 中心的Dan Avi朗道博士和生物统计学家Amylou Dueck博士和Heidi博士 我是马约诊所的科西奥雷克这里概述的职业发展计划将使Marcellino博士获得科学的 专业知识,并提高她在手稿和赠款准备的技能。这将有助于博士。 Marcellino既要实现她发表研究结果的短期目标,又要实现她发展研究的长期目标。 作为一名医生科学家,并建立了一个独立的研究计划,重点是确定新的 MPN中的治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bridget Kelly Marcellino其他文献

A Novel Three-Way Translocation Involving emETV6-IL3/em Drives AML with Eosinophilia
一种涉及 emETV6-IL3/em 的新型三方易位驱动伴有嗜酸性粒细胞增多的急性髓系白血病
  • DOI:
    10.1182/blood-2024-203588
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Ariel Siegel;Joseph Tripodi;Brianna Kelly;Sebastian Elghaity-Beckley;Michelle Becker;Douglas Tremblay;Jonathan Feld;Hannah Levavi;Marina Kremyanskaya;Bridget Kelly Marcellino;Christian Salib;Alla Keyzner;Amy Duffield;John O. Mascarenhas;Vesna Najfeld;Alan Shih
  • 通讯作者:
    Alan Shih
A Novel Three-Way Translocation Involving <em>ETV6-IL3</em> Drives AML with Eosinophilia
  • DOI:
    10.1182/blood-2024-203588
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Ariel Siegel;Joseph Tripodi;Brianna Kelly;Sebastian Elghaity-Beckley;Michelle Becker;Douglas Tremblay;Jonathan Feld;Hannah Levavi;Marina Kremyanskaya;Bridget Kelly Marcellino;Christian Salib;Alla Keyzner;Amy Duffield;John O. Mascarenhas;Vesna Najfeld;Alan Shih
  • 通讯作者:
    Alan Shih
<em>TP53</em> Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
  • DOI:
    10.1182/blood-2024-206688
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Shivani Handa;Yosef Joseph Rene Amel Riazat-Kesh;Richard J Butterfield;Ganesh Sivakumar;Sangeetha Venugopal;Erin McGovern;Jonathan Feld;Douglas Tremblay;Sebastian Elghaity-Beckley;Marina Kremyanskaya;John O. Mascarenhas;Blake Langlais;Gina L. Mazza;Daniel I. Nathan;Joseph Tripodi;Vesna Najfeld;Amylou C Dueck;Raajit Rampal;Ronald Hoffman;Bridget Kelly Marcellino
  • 通讯作者:
    Bridget Kelly Marcellino
Role of HMGA2 Overexpression Caused By Specific Genetic emHMGA2/em Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
特定遗传 emHMGA2 畸变导致的 HMGA2 过表达在钙网蛋白突变型骨髓纤维化患者疾病进展中的作用
  • DOI:
    10.1182/blood-2024-205834
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Christoph Schaniel;Shivani Handa;Joseph Tripodi;MD Babu Mia;Christian Salib;Jeff Vierstra;Allison J Cote;Daiva Ahire;Douglas Tremblay;Bridget Kelly Marcellino;John A Stamatoyannopoulos;Vesna Najfeld;Ronald Hoffman
  • 通讯作者:
    Ronald Hoffman
Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
  • DOI:
    10.1182/blood-2024-204136
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Cara Clementelli;MD Babu Mia;Sarah Haines;Christoph Schaniel;Malgorzata Olszewska;Joann Arandela;Sebastian Elghaity-beckley;Sophie Klingborg;Zinedine Hoque;Min Lu;Eirini Papapetrou;Ronald Hoffman;Bridget Kelly Marcellino
  • 通讯作者:
    Bridget Kelly Marcellino

Bridget Kelly Marcellino的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bridget Kelly Marcellino', 18)}}的其他基金

Core B: MPN-RC Tissue Bank
核心 B:MPN-RC 组织库
  • 批准号:
    10628644
  • 财政年份:
    2006
  • 资助金额:
    $ 16.44万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 16.44万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 16.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 16.44万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 16.44万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了